These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17543645)

  • 1. President's page: drug-eluting stents in contemporary practice--a call for a real-world, open-entry, device-tracking registry.
    Dove JT; Moliterno DJ; Weaver WD; Shelton ME
    J Am Coll Cardiol; 2007 Jun; 49(22):2223-6. PubMed ID: 17543645
    [No Abstract]   [Full Text] [Related]  

  • 2. Linking data from hospital and cancer registry databases: should this be standard practice?
    Field K; Kosmider S; Johns J; Farrugia H; Hastie I; Croxford M; Chapman M; Harold M; Murigu N; Gibbs P
    Intern Med J; 2010 Aug; 40(8):566-73. PubMed ID: 19460066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative clinical outcomes of paclitaxel- and sirolimus-eluting stents: results from a large prospective multicenter registry--STENT Group.
    Simonton CA; Brodie B; Cheek B; Krainin F; Metzger C; Hermiller J; Juk S; Duffy P; Humphrey A; Nussbaum M; Laurent S;
    J Am Coll Cardiol; 2007 Sep; 50(13):1214-22. PubMed ID: 17888837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-eluting stent update 2007: part I. A survey of current and future generation drug-eluting stents: meaningful advances or more of the same?
    Daemen J; Serruys PW
    Circulation; 2007 Jul; 116(3):316-28. PubMed ID: 17638940
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
    Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
    Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-year clinical outcomes with drug-eluting stents for diabetic patients with de novo coronary lesions: results from a real-world multicenter registry.
    Ortolani P; Balducelli M; Marzaroli P; Piovaccari G; Menozzi A; Guiducci V; Sangiorgio P; Tarantino F; Geraci G; Castriota F; Tondi S; Saia F; Cooke RM; Guastaroba P; Grilli R; Marzocchi A; Maresta A
    Circulation; 2008 Feb; 117(7):923-30. PubMed ID: 18250265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry.
    Marzocchi A; Saia F; Piovaccari G; Manari A; Aurier E; Benassi A; Cremonesi A; Percoco G; Varani E; Magnavacchi P; Guastaroba P; Grilli R; Maresta A
    Circulation; 2007 Jun; 115(25):3181-8. PubMed ID: 17562952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term clinical outcomes of the Drug-Eluting Stents in the Real World (DESIRE) Registry.
    Sousa A; Costa JR; Moreira AC; Cano M; Maldonado G; Costa RA; Pavanello R; Romano ER; Campos C; Haddad N; Abizaid A; Feres F; Mattos LA; Staico R; Sousa JE;
    J Interv Cardiol; 2008 Aug; 21(4):307-14. PubMed ID: 18754966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregnancy exposure registries: academic opportunities and industry responsibility.
    Wyszynski DF
    Birth Defects Res A Clin Mol Teratol; 2009 Jan; 85(1):93-101. PubMed ID: 19107953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel paclitaxel-eluting, biodegradable polymer coated stent in the treatment of de novo coronary lesions: a prospective multicenter registry.
    Buszman P; Trznadel S; Milewski K; Rzeźniczak J; Przewłocki T; Kośmider M; Wójcik J; Janczak J; Zurakowski A; Kondys M; Król M; Kinasz L; Jaklik A; Rzeszutko Ł; Kałuza GL; Kiesz S; Gil R
    Catheter Cardiovasc Interv; 2008 Jan; 71(1):51-7. PubMed ID: 18098182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiographic and clinical outcome of invasively managed patients with thrombosed coronary bare metal or drug-eluting stents: the OPTIMIST study.
    Burzotta F; Parma A; Pristipino C; Manzoli A; Belloni F; Sardella G; Rigattieri S; Danesi A; Mazzarotto P; Summaria F; Romagnoli E; Prati F; Trani C; Crea F
    Eur Heart J; 2008 Dec; 29(24):3011-21. PubMed ID: 18987096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions.
    Jensen LO; Maeng M; Kaltoft A; Thayssen P; Hansen HH; Bottcher M; Lassen JF; Krussel LR; Rasmussen K; Hansen KN; Pedersen L; Johnsen SP; Soerensen HT; Thuesen L
    J Am Coll Cardiol; 2007 Jul; 50(5):463-70. PubMed ID: 17662400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four-year clinical follow-up of the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital registry.
    Daemen J; Kukreja N; van Twisk PH; Onuma Y; de Jaegere PP; van Domburg R; Serruys PW
    Am J Cardiol; 2008 Apr; 101(8):1105-11. PubMed ID: 18394442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of the tacrolimus drug-eluting Janus stent: a prospective two-centre registry in high-risk patients.
    Romagnoli E; Leone AM; Burzotta F; Trani C; Angeloni G; Materazzo G; Niccoli G; De Vita M; Perfetti M; Mazzari MA; Mongiardo R; Rebuzzi AG; Schiavoni G; Crea F
    J Cardiovasc Med (Hagerstown); 2008 Jun; 9(6):589-94. PubMed ID: 18475127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late stent thrombosis with drug-eluting stents: the price to pay to prevent restenosis?
    Kumbhani DJ; Bavry AA; Bhatt DL
    Indian Heart J; 2007; 59(2 Suppl B):B113-7. PubMed ID: 19153427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [two-year ClOpidOgrel need] study).
    Tanzilli G; Greco C; Pelliccia F; Pasceri V; Barillà F; Paravati V; Pannitteri G; Gaudio C; Mangieri E
    Am J Cardiol; 2009 Nov; 104(10):1357-61. PubMed ID: 19892050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry.
    Garg P; Normand SL; Silbaugh TS; Wolf RE; Zelevinsky K; Lovett A; Varma MR; Zhou Z; Mauri L
    Circulation; 2008 Nov; 118(22):2277-85, 7p following 2285. PubMed ID: 19001019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achieving a quality trauma database.
    Petrovick L
    J Trauma Nurs; 2004; 11(3):122-5. PubMed ID: 16512273
    [No Abstract]   [Full Text] [Related]  

  • 19. Rates of stent thrombosis in bare-metal versus drug-eluting stents (from a large Australian multicenter registry).
    Yan BP; Duffy SJ; Clark DJ; Lefkovits J; Warren R; Gurvitch R; Lew R; Sebastian M; Brennan A; Andrianopoulos N; Reid CM; Ajani AE;
    Am J Cardiol; 2008 Jun; 101(12):1716-22. PubMed ID: 18549846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Off-label use of drug-eluting stents putting it in perspective.
    Grines CL
    J Am Coll Cardiol; 2008 Feb; 51(6):615-7. PubMed ID: 18261679
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.